Entry Detail


General Information

Database ID: LDA0004521
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Yes

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:CARMN
Full Name:cardiac mesoderm enhancer-associated non-coding RNA
Category:LncRNA
Species:Homo sapiens
Synonyms:CARMEN|MIR143HG
Chromosome:5
Strand:+
Coordinate:
Start Site(bp):149406845End Site(bp):149432836
External Links:
Ensembl ID:ENSG00000249669
Ensembl Transcript ID:N/A
Entrez Gene:728264.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:18   
More Information
Causal Disease Number:12
Network:
Top Causal Diseases:
Carcinoma, Hepatocellular  (Score: 0.985791)
Carcinoma, Hepatocellular  (Score: 0.985791)
Endometrial Neoplasms  (Score: 0.959542)
Endometrial Neoplasms  (Score: 0.959542)
Urinary Bladder Neoplasms  (Score: 0.731059)
Uterine Cervical Neoplasms  (Score: 0.731059)
Glioblastoma  (Score: 0.731059)
Triple Negative Breast Neoplasms  (Score: 0.731059)
Urinary Bladder Neoplasms  (Score: 0.731059)
Uterine Cervical Neoplasms  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:3068D005909
Disease Name:glioblastomaGlioblastoma
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes.A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Alias:GBM//adult glioblastoma multiforme//grade IV adult Astrocytic tumor//primary glioblastoma multiforme//spongioblastoma multiformeGlioblastoma//Glioblastomas//Astrocytoma, Grade IV//Astrocytomas, Grade IV//Grade IV Astrocytoma//Grade IV Astrocytomas//Glioblastoma Multiforme//Giant Cell Glioblastoma//Giant Cell Glioblastomas//Glioblastoma, Giant Cell//Glioblastomas, Giant Cell

 

Disease Association Statistics

Total Associated ncRNA Number:296   
More Information
Causal ncRNA Number:252
Network:
Top Causal ncRNAs:
DLEU1  (Score: 0.999893)
LINC-ROR  (Score: 0.999893)
MALAT1  (Score: 0.999893)
HOTAIRM1  (Score: 0.999893)
LINC-ROR  (Score: 0.999893)
MALAT1  (Score: 0.999893)
HOTAIRM1  (Score: 0.999893)
DLEU1  (Score: 0.999893)
hsa_circ_0029426  (Score: 0.985791)
DLGAP1-AS1  (Score: 0.985791)
More Information

 

Evidence Support

Strong Evidence:Cell Proliferation Assay//qRT-PCR//Western Blot
Weak Evidence:

 

Reference

[1] PubMed ID:33461388
Disease Name:Glioblastoma
Sample:GBM tissues
Dysfunction Pattern:Interaction(miR-504/p53 )
Validated Method:Cell Proliferation Assay//qRT-PCR//Western Blot
Description:We found that miR143HG was downregulated in GBM and predicted poor survival.
Causality:Yes
Causal Description:Moreover, overexpression of miR143HG and p53 decreased GBM cell proliferation, while overexpression of miR-504 increased GBM cell proliferation. In addition, overexpression of miR-504 attenuated the effect of miR143HG overexpression on GBM cell proliferation.
Clinical-realted Application: We found that miR143HG was downregulated in GBM and predicted poor survival. The mRNA expression levels of miR143HG and p53 were positively correlated in GBM tissues.Bioinformatics analysis suggested that miR143HG could form base paring with miR-504, which has been reported to target p53.